Esperion Therapeutics ESPR Royalty Purchase Agreement
Royalty Purchase Agreement at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:DeferredTaxAssetRoyaltyPurchaseAgreement.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's royalty purchase agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's royalty purchase agreement?
- Esperion Therapeutics (ESPR) reported royalty purchase agreement of $72.6M in Q4 2025.
- What does royalty purchase agreement mean?
- This represents the tax basis associated with assets acquired through royalty purchase agreements. It captures the deferred tax impact of accounting for royalty rights as financial assets or intangible assets for tax purposes. This metric is critical for understanding the tax implications of the company's long-term intellectual property monetization strategy.